Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS") Dec 8, 2020
Citius Pharmaceuticals to Present Corporate Update at Benzinga Global Small Cap Conference on December 8 Dec 3, 2020
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components Nov 30, 2020
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) Oct 7, 2020
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial Sep 29, 2020
Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok® Sep 22, 2020
